Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
OBJECTIVE
To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.


METHODS
A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998-2006, with particular focus on the most recent years (2002-2006).


METHODS
Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.


RESULTS
Over the period 1998-2006, 522 autologous HSCT procedures (41%) and 737 allogeneic procedures (59%) were performed. About 60% of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34% of allogeneic transplants in 2006 using cord blood. Over the period 2002-2006, the median age of patients receiving transplants was 7 years (range, 0-19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33%) and acute myeloid leukaemia (24%). The most common indications for autologous HSCT were neuroblastoma (23%), medulloblastoma (21%) and Ewing sarcoma (10%). TRM at 1 year after transplant was 22% for alternative donor transplants, 7% for matched-sibling transplants and 5% for autologous transplants. Relapse or persistence of a child's underlying condition accounted for 54% of all deaths within 1 year after transplant.


CONCLUSIONS
HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.
Moore
Andrew S
AS
Oncology/Haematology Service, Royal Children's Hospital, Brisbane, QLD.
Shaw
Peter J
PJ
Hallahan
Andrew R
AR
Carter
Tina L
TL
Kilo
Tatjana
T
Nivison-Smith
Ian
I
O'Brien
Tracey A
TA
Tapp
Heather
H
Teague
Lochie
L
Wilson
Shaun R
SR
Tiedemann
Karin
K
D000293:Adolescent; D000328:Adult; D001315:Australia; D016026:Bone Marrow Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D009520:New Zealand; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012042:Registries; D012189:Retrospective Studies; D017741:Survivors; D055815:Young Adult